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Abstract 
Objective:  To describe the design and implementation of an elective course in drug discovery, development, and commercialization 
for pharmacy, medical, biomedical graduate, business, and law students.  Case Study:  This course included didactic lectures, student 
group discussions, a longitudinal assignment, and a question and answer panel session.  A 9-item instrument using a 5-point 
response scale was used for course evaluation.  The longitudinal assignment was the creation and presentation of a product lifecycle 
strategic plan (PLSP).  Respondents rated ‘agree’ and ‘strongly agree’ in the course providing useful information on drug discovery 
(39% and 53%), drug development (39% and 60%), and drug commercialization (33% and 60%).  The majority of student-reported 
overall understanding of the drug discovery and drug development process was rated ‘very good’ (49% and 46%), while the drug 
commercialization process was rated ‘good’ (46%).  Conclusions:  An elective course on drug discovery, development, and 
commercialization included enrollment of students with diverse educational training.  The course provided useful information and 
improved overall student understanding.     
 
 
Introduction 
In 2011, 3.7 billion prescriptions were dispensed, averaging 
approximately 12 prescriptions per person in the United 
States.
1
  The United States Food and Drug Administration 
(FDA) approved 35 new medicines during the 2011 fiscal year, 
which was the highest number of approvals in the past 
decade.
2
  Although recently approved drugs have addressed 
unmet medical needs and have improved morbidity and 
mortality, drug development remains an expensive and time-
consuming process.  Pharmaceutical companies spend 
approximately $1.5 billion over 10 years to develop a drug, 
with approximately 11% of all drugs in development 
successfully receiving post-marketing approval.
3, 4
   
 
Drug discovery, development, and commercialization is a 
complex, multiple-step, sequential process.  Numerous 
activities include, but are not limited to, the discovery of 
novel agents, conducting preclinical animal and toxicology 
studies, designing and completing clinical studies (e.g. Phase 
1, 2, and 3), submitting regulatory documents (e.g. 
Investigational New Drug [IND], New Drug Application [NDA]), 
and initiating post-approval commitments (e.g. Phase 4 
studies, adverse drug reaction monitoring, post-approval  
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manufacturing inspections).  Successful completion of these 
activities requires a team-orientated, interdisciplinary 
approach involving the expertise of individuals with advanced 
training and formal education in pharmacy, medicine, 
biomedical sciences, law and/or business.
5
 
 
For example, pharmacists rely on pharmacokinetics 
knowledge such as elimination half-life and clearance to 
determine appropriate starting doses and dosing intervals for 
clinical studies.  Understanding a drug’s absorption, 
distribution, metabolism, and excretion properties are critical 
for protocol development in identifying exclusionary 
medications based on similar mechanisms of action and/or 
potential for drug-drug interactions.  Physicians are 
responsible for establishing specific ‘cut off’ laboratory values 
and in identifying co-morbid diseases when determining 
inclusion and exclusion criteria.  Biomedical researchers 
evaluate novel biomarkers and rely on laboratory methods 
and techniques previously acquired or learned during 
graduate school.  Lawyers are essential in providing expertise 
in patent strategy and patent law.  Professionals with 
advanced training in health economics and outcomes 
research are needed to assess needs of reimbursement 
authorities and build evidence to support product value.  
Individuals possessing formal business training are 
responsible for developing product portfolio strategies and in 
facilitating completion of product lifecycle strategic plans 
(PLSPs).  These activities, although quite distinct, are shared 
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among all team members and point to the common goal of 
obtaining drug approval.   
 
There are few reports of the teaching of drug discovery, 
development, and commercialization to students.
6-10
  In the 
Accreditation Council on Pharmaceutical Education (ACPE) 
accreditation standards, drug discovery and development are 
suggested, but not required, science foundations in the 
pharmaceutical sciences.
11
  Additionally, there is no mention 
of the teaching of drug commercialization.  Consequently, the 
lack of including these topics in a school curriculum may 
adversely impact students who are interested in career 
opportunities at a pharmaceutical and/or biotech company.  
Evidence of student interest in this area exists based on the 
availability and sustainability of joint pharmacy-
pharmaceutical post-doctoral fellowship programs.
12
   
 
In 2009, the University of California, San Diego (UCSD), Skaggs 
School of Pharmacy and Pharmaceutical Sciences (SSPPS) 
developed an elective course titled Drug Discovery, 
Development, and Commercialization.  The purpose of this 
paper is to describe the design and implementation of this 
elective course offered to UCSD pharmacy, medical, 
biomedical graduate, and business students, as well as 
University of California, Irvine (UCI) law students. 
 
Course Design   
The course was developed by two pharmacy faculty serving 
as course co-chairs who were previously employed at various 
pharmaceutical/biotech companies.  The co-chairs desired 
local pharmaceutical/biotech employees to provide a portion 
of didactic lecture content.  Due to the lack of didactic 
teaching experience of some of the selected lecturers, 
educational resources (e.g. how to write goals and objectives) 
were provided.  The remaining lecturers were SSPPS faculty 
who had previous experience in the pharmaceutical/biotech 
industry serving as an employee or as a consultant.  
 
This was a 3-unit (30 in-class hours) elective that utilized a 
Satisfactory/Unsatisfactory grade.  Course grades were 
determined by attendance (50% of grade) and a formal oral 
presentation of a PLSP (50% of grade). The elective was 
conducted once weekly in the afternoon for 10 weeks.  The 
first two hours of each week were dedicated to didactic 
lecture, while the third hour was dedicated to student groups 
working on the PLSP.  In 2012, an audio and video feed was 
set up to enable remote participation for law students.  Video 
and audio equipment included a LifeSize™ 4x HD camera, 
Lifesize™ codec, wireless remote control, and microphone 
setup.  Dual HDTVs were set up; with one to view the MS 
Powerpoint ™ presentation and the second HDTV to view the 
lecturer and law students.  Law students were also invited to 
attend the lecture in-person, but few were able to attend due 
to the commute time between UCI and UCSD (approximately 
60 minutes each way).  During the last week of the course, 
PLSP presentations were conducted with course co-chairs and 
students in attendance.  Each PLSP presentation was limited 
to 45 minutes and each student group was required to 
present a component of the PLSP.  For the law students, they 
were provided the option of presenting in-person or via audio 
and video teleconferencing. 
 
Learning Objectives 
The course was offered once each academic year starting in 
2010.  The course focused in areas related to discovery, 
development, and commercialization of a drug.  The course 
objectives were to: 
1. Differentiate between small molecule and biological agent 
discovery processes; 
2. Identify the tools and methodologies utilized in the drug 
discovery process; 
3. Identify the required pre-clinical studies needed for drug 
approval; 
4. Compare and contrast phase I, II, III, and IV clinical trials;  
5. Describe the regulatory process for an investigational new 
drug (IND) application and new drug application (NDA);  
6. Identify components of a commercialization strategy and 
marketing plan; 
7. Develop a product lifecycle strategic plan (PLSP). 
Learning objectives 1 and 2 were created based on previous 
literature describing the evaluation of drug discovery and the 
impact of new technologies being used for drug discovery.
13, 
14
  Learning objectives 3, 4, and 5 were created based on FDA 
Drug Guidance documents which represent current thinking 
of the FDA on a particular subject.
15
  Learning objectives 6 
and 7 were developed based on the commonality and 
frequency of use within pharmaceutical/biotech companies.   
 
Student Participants 
To enroll in the course, pharmacy, business, and biomedical 
graduate students needed to be in at least their second year, 
while medical and law students in their first year of their 
respective curriculum.  One individual was identified from 
each school to facilitate enrollment and maintain a list of 
students who enrolled.  When the course was first offered in 
2010, there was a maximum enrollment of 24 students (e.g. 6 
students from each school).  During the subsequent quarters, 
the maximum enrollment increased to 30 students.  Law 
students first enrolled in the course in 2012.  The prerequisite 
for enrolling students in a specific year of their program and 
class size limitation was done to ensure an interactive, small 
group learning environment.  One exception was made in 
2012 as a first year pharmacy student who had previous work 
experience at a large pharmaceutical company was allowed 
Case Study EDUCATION 
 
http://z.umn.edu/INNOVATIONS               2013, Vol. 4, No. 3, Article 121                              INNOVATIONS in pharmacy   3 
 
to enroll.  In the event that student enrollment limits were 
not met from a professional or graduate school, students 
from other schools were enrolled at the discretion of the 
course co-chairs.   
 
Curriculum Content 
Lecture topics are summarized in Table 1.  The course utilized 
a variety of teaching and learning methods, including didactic 
teaching, interactive student groups, a longitudinal 
assignment, and a question and answer panel session.  There 
was no required textbook but recommended readings were 
provided for each lecture topic.  Six hours of didactic lecture 
were dedicated to drug discovery.  These lectures were 
presented first.  Subsequent lectures included 8 hours for 
drug development and regulatory affairs, and 5 hours for 
pharmacoeconomics and drug commercialization.  With 
regards to the design, a significant amount of information 
could be included as course content.  The challenge was to 
determine specific topics for 20 didactic hours to be divided 
in discovery, development, and commercialization.  Previous 
reports of drug development courses were valuable in 
determining lecture topics/content.  For example, 4 hours 
were dedicated to early and late stage clinical development 
(e.g. Phase 1, 2, 3, and 4 clinical trials) as previous reports 
consistently selected these topics.
7, 8
  
 
Upon completion of all didactic lectures, a question and 
answer panel session was conducted.  Panel members were 
biomedical graduate-, medically-, and pharmacy-trained 
individuals currently employed at a pharmaceutical/biotech 
company.  Panel members provided examples of how 
knowledge acquired from past didactic and clinical training 
were relevant to drug discovery, development, and 
commercialization.  The panel also provided a perspective of 
their own career paths within the pharmaceutical company 
and current job responsibilities.   
 
PLSP Assignment 
Students were assigned into groups of 4 to 5 and were 
provided a drug to develop a PLSP presentation.  Although an 
ideal group would be composed of a student from each 
discipline, this was not possible.  However, each group had at 
least two different disciplines represented in each group.  
During the in-class time to work on the PLSP presentation, 
groups would review and discuss relevant literature related 
to the assigned drug.  Groups were encouraged to discuss 
PLSP content with course co-chairs and lecturers, of which 
several lecturers were available to students during the 
dedicated PLSP in-class time.  Students were also encouraged 
to engage in debate and practice their oral communication 
skills in preparation for the PLSP presentation. 
 
Based on personal experience as previous employees for 
pharmaceutical and/or biotech companies, the co-chairs 
selected the drugs in specific categories for the PLSP.  Drug 
selection for PLSP presentation was based on the desire for 
student exposure related to development of a small molecule 
(e.g. atorvastatin, rosiglitazone) and biologic (e.g. infliximab), 
the withdrawal of a drug due to safety concerns (e.g. 
rofecoxib, cerivastatin), novel commercialization/marketing 
strategies (e.g. epoetin alfa), and transition of a drug to over-
the-counter status (e.g. omeprazole).  These drugs continued 
to be used for PLSP presentation in the subsequent academic 
years.  PLSP presentation required discussion of the following 
sections: drug background, product portfolio planning, 
preclinical and clinical development strategy, formulation 
development, regulatory strategy, and a 
commercialization/marketing plan.  Specific content for 
students to address in each section of the PLSP presentation 
is summarized in Table 2.    
 
Student Perceptions 
There were 24, 25, and 23 students enrolled in the course 
during the 2010, 2011, and 2012 academic years, 
respectively.  The profile of students was 36% (n=26) 
pharmacy, 28% (n=20) business, 22% (n=16) biomedical 
graduate, 10% (n=7) medical and 4% (n=3) law.  A 9-item 
survey instrument using a 5-point response scale was 
developed based on a previous survey instrument for a 
finance elective course.
16
  The instrument was administered 
to students at the end of the course to assess objectives, 
content organization, usefulness, and overall 
recommendations (Table 3).  UCSD IRB (#10125) approval 
was obtained and students provided written informed 
consent prior to evaluating the course.  Fifty-seven students 
completed the survey instrument (79% response rate).  
Survey respondents were 37% (n=21) pharmacy, 26% (n=15) 
biomedical graduate, 25% (n=14) business, and 12.3% (n=7) 
medical students.  Course evaluation measures are 
summarized in Table 3.  The majority of students rated 
‘agree’ or ‘strongly agree’ that the course was well organized 
(61% and 26%), included interpretation and application of 
information (68% and 26%), and provided an unbiased 
perspective (63% and 23%).  Ninety-three percent of students 
rated at least ‘agree’ in recommending this course to other 
students and in rating this course highly.  However, it should 
be noted that there were no law students who completed the 
survey instrument.  Consequently, one is not able to 
determine if similar course outcomes were achieved by law 
students.  Thirty-three percent, 49%, and 14% of students 
reported overall understanding of the drug discovery process 
as ‘good’, ‘very good’, and ‘excellent’, respectively.  Overall 
understanding of the drug development and 
commercialization processes was predominantly rated as 
Case Study EDUCATION 
 
http://z.umn.edu/INNOVATIONS               2013, Vol. 4, No. 3, Article 121                              INNOVATIONS in pharmacy   4 
 
‘very good’ (46% and 33%) or ‘good’ (32% and 46%) (Table 4).  
Regarding the usefulness of program components, the 
majority of students rated the PLSP presentation (49%) and 
question and answer panel session (46%) as ‘useful’.   
 
Lessons Learned 
Two key implementation aspects were to have this course 
cross-listed and to have a staff individual from each school 
assist with enrollment.  Cross-listing the course is the creation 
of a different course number for each school.  This was the 
preferred method by non-pharmacy schools.  For each 
school, course elective descriptions are available online.  If a 
student was unable to attend the course information session, 
then the only way for a student to be aware of the course is 
by online searching of all offered electives.  If the course was 
only listed with a SSPPS number, students from non-
pharmacy schools would not be able to access the course 
online.  Individuals who assisted with enrollment had detailed 
knowledge of their school curriculum and student schedule to 
help facilitate the best date/time to conduct the course.  
They also served as the first contact with the student, were 
able to triage student questions (e.g. grading requirements, 
classroom location), and defer student questions about 
course content to the course co-chairs.  
 
One perceived strength by the course co-chairs was the 
selection of lecturers employed at local 
pharmaceutical/biotech companies.  These individuals 
provided expertise for several topics, with many of these 
lecturers having at least 10 years of experience.  Many of 
these lecturers not only provided adequate teaching of basic 
concepts, but also were able to provide case examples for 
emphasis of key concepts.  Concern was expressed from 
school faculty of the potential for bias in selecting lecturers 
employed at a pharmaceutical/biotech industry.  Previous 
drug development courses offered to students have utilized 
individuals from the pharmaceutical/biotech industry to 
provide lecture content.
7, 8
  However, these reports provide 
no data on whether there was student perceived bias.  
Regarding the course, there were 20 hours of didactic lecture, 
with individuals from the pharmaceutical/biotech industry 
providing 8 to 11 didactic hours.  The course co-chairs 
communicated to all lecturers the desire to minimize bias in 
their presentation and reviewed presentation content prior 
to providing to the students.  Furthermore, the majority of 
students reported the course provided an unbiased 
perspective (Table 3).  Consequently, the concern for bias in 
selecting lecturers from the pharmaceutical/biotech industry 
is minimal and should be encouraged for future course 
development.  
 
The number of medical students enrolled in the course was 6, 
0, and 1 for 2010, 2011, and 2012, respectively.  We 
speculate that the primary reason for the low medical 
student enrollment in 2011 and 2012 was due to 
implementation of a revised medical school curriculum in the 
fall of 2011, which resulted in decreased medical student 
availability.  We also observed a low number of enrolled law 
students in 2012.  This may be due to the lack of relevant 
content, thus negating law student interest.  In 2013, the 
course co-chairs revised the didactic lectures to include 
discussion of intellectual property and patent strategy to 
provide relevant content for law students.   
 
The majority of students rated the question and answer panel 
session as ‘useful’ (Table 3).  It may be possible that speakers 
who were not specific to the student’s profession (e.g. 
physician speaking to a business student), may not be 
perceived as ‘useful’ by the student.  One modification being 
considered is to decrease the time for a panel session and to 
allocate the extra time to have the speakers meet with 
students who are in the same profession.   
 
Implications of the PLSP Assignment 
The PLSP assignment was created for students to actively 
work together to prepare them for the multidisciplinary 
environment similar to what one would expect for a project 
team in a pharmaceutical/biotech company.  PLSPs are 
commonly performed in a pharmaceutical/biotech company.  
Members of the project team are responsible for providing 
written and verbal input on specific content, which is then 
used by upper management in making key decisions for the 
drug under development.  As described in Table 2, specific 
content includes, but is not limited to, preclinical, clinical, and 
regulatory strategy.  Often such content are provided by a 
project team member with training in a specific discipline.  
Consequently, it was critical for the course to enroll students 
from different disciplines to fully maximize the PLSP 
assignment.  Student input and perspective was expected to 
vary based on formal training.  For example, business, but 
few pharmacy and medical students, readily identified a 
SWOT analysis, drug value proposition, and drug positioning 
statement.  In contrast, pharmacy and medical students 
readily identified phase 3 primary and secondary endpoints 
and key clinical study design aspects.   
 
The majority of students rated the PLSP assignment as 
‘useful’ (Table 3).  One challenge of the PLSP project was the 
difficulty of obtaining relevant literature on a specific drug for 
a PLSP.  Students were familiar with searching for research 
articles on PUBMED, but were unaware and/or unfamiliar 
with regulatory and financial websites.  Future revisions to 
the PLSP assignment are to include an example PLSP 
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presentation as course material, highlight suggested websites 
to obtain PLSP information, and provide recommended 
readings regarding PLSPs.   
 
Future Direction and Research 
Interest has been expressed to provide this elective as an 
online course.  There has been significant adoption of 
internet-based instruction with the proliferation of massive 
online open courses (MOOCs).  MOOCs are a distance 
learning model providing large-scale interactive participation.  
Instructional design approaches include peer-review, group 
collaboration, and automated quizzes and exams.
17
  
Significant developments have occurred, such as increased 
acceptance by higher education institutions and the ability to 
obtain course credit.
18
   
 
In April 2013, this elective was made available as a MOOC.
19
  
One key difference between the MOOC and ‘live’ course was 
the lack of student prerequisites for the MOOC.  This was 
done to maximum student interest and enrollment.  Live 
lectures were videotaped, edited by on campus media 
consultants, and then uploaded onto a website.  Multiple 
choice quizzes for each lecture were implemented for the 
MOOC.  Regarding the PLSP presentation, an informational 
video presentation was developed for the students.  Students 
self-organized into groups by communicating through a 
posted, discussion forum.  PLSP presentations in 
PowerPoint™ format with audio were uploaded into a 
website for review.  A grading rubric for the PLSP 
presentation was developed and implemented (Appendix 1) 
for the MOOC, which will also be adapted for the ‘live’ 
elective course.     
 
Although our primary intention of the MOOC was to provide 
a course to students from other Schools/Colleges of 
Pharmacy where a course on drug discovery, development, 
and commercialization was not offered, students from 
various disciplines and educational backgrounds enrolled in 
the MOOC.  The co-chairs speculate that offering such as 
course would spur not only pharmacy student interest, but 
interest from students with different educational 
backgrounds to potentially look beyond his/her traditional 
work practices.  In our experience with meeting SSPPS 
students, several have expressed interest in the 
pharmaceutical/biotech industry, but lack sufficient 
background and depth of pharmacist roles, responsibilities, 
and expectations when employed for such industries.  
Whether or not such as course leads to an increase in 
pursuing postdoctoral pharmaceutical fellowships remains an 
intriguing area of future research.  We hope that a course on 
drug discovery, development, and commercialization allows 
students to foster an appreciation for the process and to be 
better informed about the safety, efficacy, and economic 
aspects of novel drugs and treatments.   
 
Conclusion  
Drug discovery, development, and commercialization is a 
complex process requiring an interdisciplinary approach 
involving individuals with advanced training and formal 
education in pharmacy, medicine, biomedical sciences, law, 
and business.  Offering an interdisciplinary elective course to 
students is an opportunity to increase understanding of the 
drug discovery, development, and commercialization process.  
Didactic teaching, interactive student groups, a longitudinal 
assignment, and a question and answer panel session were 
instrumental in the implementation of the elective course.  
The course provided useful information in the drug discovery, 
development, and commercialization process, with student-
reported understanding in these areas.  
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Table 1. Didactic lectures for elective course in drug discovery, development, and commercialization 
Lecture Topic     
1. Current state of affairs of the pharmaceutical/biotech industry 
2. Development of a life cycle strategic plan and intellectual property strategy 
3. Drug targets and tools during preclinical development 
4. Role of genomics and proteomics in drug discovery 
5. Compound selection and preclinical studies 
6. Impact of translational research in drug discovery 
7. Clinical development: Strategy and design 
8. Role of the Food and Drug Administration (FDA) and overview of the Investigational New Drug (IND) process 
9. Formulation development and manufacturing 
10. Clinical study start-up activities 
11. Clinical trials: Phase 1,2,3,4 
12. Pharmacoeconomics in drug development 
13. New Drug Application (NDA) filing and product labeling 
14. Drug commercialization strategies 
15. The value of marketing research 
16. Business development in the pharmaceutical/biotech industry 
17. Managed care and sales strategies 
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Table 2. Content specifics for the student group product lifecycle strategic plan 
 
Section 
1. The Market 
a. State if the drug addresses an unmet medical need 
b. Determine if there is a market opportunity for the drug 
c. Summarize benchmarking analysis information 
d. Summarize competitive landscape for the drug 
 
2. Preclinical 
a. Summarize current product profile 
b. Identify mechanism of action 
c. Summarize animal data regarding pharmacokinetic data, efficacy, and toxicity 
d. Describe current dosage forms and route of administration 
 
3. Early clinical development 
a. Summarize phase 1 safety and tolerability data 
b. Summarize human pharmacokinetic properties of drug  
c. Summarize phase 2 dose finding or dose ranging study findings 
d. Determine recommended starting dose and dose frequency from phase 1 and 2 studies 
 
4. Late clinical development 
a. Identify phase 3 primary and secondary endpoints 
b. Describe phase 3 clinical study design 
c. Provide additional safety data from phase 3 clinical studies 
d. Summarize finding of pharmacoeconomic studies  
 
5. Regulatory strategy 
a. State which regulatory agencies have approved the drug 
b. Determine if a local or global regulatory strategy was implemented 
c. State 1 indication the drug is approved for 
d. State approved dosage form and dosing schedule 
e. Identify anticipated or desired patient population 
 
6. Marketing strategy 
a. Determine appropriateness of the drug’s marketing strategy 
b. Describe the market at the time of drug launch 
c. Interpret strength, weaknesses, opportunities, and threats (SWOT)  
d. Develop a drug value proposition 
e. Develop a drug positioning statement 
f. Identify pricing strategy  
  
7. Sales strategy & managed markets 
a. Describe sales strategy 
b. Identify the sales tactics or methods when the drug was first launched 
c. Describe advertising campaigns 
d. Summarize sales volume of drug 
e. Determine stage of the life of the drug (e.g. Introduction, growth, maturity, decline) 
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Table 3. Course evaluation scores completed by students enrolled 
 in drug discovery, development, and commercialization elective (n = 57). 
 
              Student Response, n (%)       
Item       Strongly  Disagree  Neutral  Agree  Strongly 
     Disagree        Agree 
Course objectives were clear    0 (0)  1 (2)  3 (5)  32 (56)  21 (37)  
Course content was well organized   0 (0)  0 (0)  7 (12)  35 (61)  15 (26)  
Course included interpretation and    0 (0)  2 (4)  1 (2)  39 (68)  15 (26)  
 application of information 
Course provided an unbiased perspective  1 (2)  1 (2)  6 (11)  36 (63)  13 (23)  
Course provided useful information on: 
drug discovery    0 (0)  0 (0)  5 (9)  22 (39)  30 (53)  
drug development    0 (0)  0 (0)  1 (2)  22 (39)  34 (60)  
drug commercialization   0 (0)  0 (0)  4 (7)  19 (33)  34 (60)  
I would recommend this course to other students 0 (0)  0 (0)  4 (7)  26 (46)  27 (47)  
Overall, I rate this course highly   0 (0)  0 (0)  4 (7)  20 (35)  33 (58)  
 
 
 
 
Table 4. Student-reported understanding and usefulness of various program components (n = 57). 
 
                                         Student Response, n (%) 
Item       Poor  Fair  Good  Very                Excellent 
           Good 
Overall understanding of the drug discovery process 0 (0)  2 (4)  19 (33)  28 (49)  8 (14) 
Overall understanding of the drug development process
 
0 (0)  3 (5)  18 (32)  26 (46)  10 (18) 
Overall understanding of the drug commercialization  0 (0)  5 (9)  26 (46)  19 (33)  7 (12) 
                  process         
  
Not at all  Not   Neutral  Useful  Very 
      Useful  Useful      Useful 
Product lifecycle strategic plan presentation  0 (0)  2 (4)  19 (33)  28 (49)  8 (14) 
Question and answer panel session
   
0 (0)  3 (5)  18 (32)  26 (46)  10 (18) 
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Appendix 1. Grading rubric for student group product lifecycle strategic plan 
 
Criteria      Scale    
      2 = excellent; 1 = average; 0 = poor 
Presentation Content 
The market     0 1 2 
Preclinical      0 1 2 
Early clinical development    0 1 2 
Late clinical development    0 1 2 
Regulatory strategy    0 1 2 
Marketing strategy    0 1 2 
Sales strategy and managed markets  0 1 2 
 
Presentation Style 
Each student created section of presentation 0 1 2 
Organization of presentation   0 1 2 
Quality of presentation materials    0 1 2 
Poise of verbal delivery of presentation  0 1 2 
Grammar and punctuation of presentation  0 1 2 
Thoroughness of presentation   0 1 2 
Clarity of presentation    0 1 2 
Perceived student knowledge of the drug  0 1 2 
 
 
Total possible points (maximum of 30 points) 
 
 
 
